NCT05109598View on ClinicalTrials.gov

Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell)

PHASE2CompletedINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

November 4, 2021

Primary Completion Date

February 14, 2022

Study Completion Date

April 6, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

Recombinant new coronavirus vaccine (CHO cell)

Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person /dose Recombinant new coronavirus vaccine (CHO cells).

Trial Locations (1)

411228

Hunan Provincial Center for Disease Control and Prevention, Changsha

All Listed Sponsors

lead

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY

NCT05109598 - Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell) | Biotech Hunter | Biotech Hunter